%0 Journal Article
%T A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
%A Defferrari Carlotta
%A Campora Sara
%A D'Amico Mauro
%A Piccardo Arnoldo
%A Biscaldi Ennio
%A Rosselli Daniela
%A Pasa Ambra
%A Puntoni Matteo
%A Gozza Alberto
%A Gennari Alessandra
%A Zanardi Silvia
%A Lionetto Rita
%A Bandelloni Michela
%A De Censi Andrea
%J Journal of Ovarian Research
%D 2012
%I BioMed Central
%R 10.1186/1757-2215-5-17
%X We treated 15 patients, mostly with platinum resistant EOC, who had received a median of four prior cytotoxic regimens, with bevacizumab 5¨C7.5£¿mg/kg q21 days in combination with either carboplatin (n£¿=£¿8), oral cyclofosfamide (n£¿=£¿5) or weekly paclitaxel (n£¿=£¿2). Bevacizumab was administered until disease progression. Tumor response was assessed by CA125 and fusion 18£¿F-FDG PET/contrast enhanced CT.The median number of bevacizumab cycles was 21 (range 3¨C59). The median baseline CA125 was 272 U/ml and decreased to 15.2 U/ml at nadir. Tumor response was 4 complete response (CR) (26.7%) and 7 partial response (PR) (46.7%) by chemotherapy (CT), with an overall response rate of 73.4% (95% CI, 51.0 ¨C 95.8) according to Response Evaluation Criteria In Solid Tumors (RECIST), and 6 CR (40%) and 4 PR (26.7%) by PET, for an overall metabolic response rate of 67% (95%CI, 42.8 ¨C 90.6) according to PET Response Criteria in Solid Tumors (PERCIST). Median progression free survival (PFS) was 21£¿months and median overall survival (OS) was 24£¿months. Grade 3 adverse events related to bevacizumab were hypertension (n£¿=£¿2), proteinuria (n£¿=£¿1) and epistaxis (n£¿=£¿5). Treatment was delayed in five patients for nasal bleeding or uncontrolled hypertension.Low-dose bevacizumab and chemotherapy was well tolerated and active in a heavily pretreated population of advanced EOC. Further studies should assess the activity of low dose bevacizumab in EOC.
%U http://www.ovarianresearch.com/content/5/1/17/abstract